Downloading...
Download

SAVA

Chaos Theory and Fractals: A forgotten name in HealthcareAbout the Tickers: Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. Phase 3 trial of Lenabasum in Systemic Sclerosis was unsuccessful last year. Currently, a phase 3 trial in Dermatomyositis is scheduled to read out top line results by Q2 2021. The Chart: Appears similar to Cassava NASDAQ:SAVA which also saw setbacks and plunged to about $1 a share. Can we use fractals and chaos theory to predict the price of $CRBP stock in the near term? Possibly. Corbus Pharmaceuticals ($CRBP) is currently trading at about $2 a share. Cassava Sciences ($SAVA) is trading at about $54 a share.
NASDAQ:CRBP
by FVCapitalManagement
1
It's unbelievable where this is sitting right now..This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100.. Still, many times, you question whether these sharp intraday rallies are the product of market manipulation, as they always seem to happen immediately before heavy sell offs, but who knows..
NASDAQ:NVAX
by stocktradez6
SAVA - Above MA's Possible 15% TargetCassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. SHORT INTEREST 1.64M 08/30/19 P/E Current -2.07 P/E Ratio (with extraordinary items) -5.00 Average Recommendation: BUY Average Target Price: 3.00
NASDAQ:SAVALong
by DEXWireNews
9 Million Warrants Priced At 1.62. Short, Medium size, Entry 3/4The Stated Value of the Preferred Shares is $20.00 per unit, and the annual interest payment, which is to be paid out in quarterly installments, is 8%". That translates into $2,000,000 worth of shares per year. In regards to the warrants, if we multiply 7.41 by 1 250 000, we get 9,262,500 common shares, and it says that the warrants are exercisible ***immediately @ $1.62 per share*** During the 60 days prior to May 31, 2019, and from the Event Date to the date hereof, Arosa Capital, on behalf of Arosa Opportunistic Fund, sold 178,333 shares of Common Stock, as follows: Date Quantity Price Type of Transaction May 2, 2019 159,955 $0.9074 Open Market Sale May 3, 2019 18,378 $0.9165 Open Market Sale Says a lot about how much confidence they had in the valuation at that time, and this was before Trump pumped it on twitter. On May 31, 2019, the Company entered into a Subscription Agreement with Arosa Opportunistic Fund, in which Arosa Opportunistic Fund purchased (i) 305,000 shares of Series B Preferred Stock, with a stated value of $20.00 per share (the “Stated Value”) and a par value of $0.001 per share (the “Preferred Stock”), and (ii) warrants to purchase up to 2,260,050 shares of Common Stock at an exercise price of $1.62 per share (the “2019 Warrants” and together with the 2018 Warrants, the “Warrants”), subject to the Exercise Limitation. The Preferred Stock is not convertible and does not hold voting rights. The Preferred Stock is entitled to annual dividends at a rate equal to 8.0% simple interest per annum on the Stated Value. Accrued dividends are payable quarterly in shares of Common Stock based on a share price of $1.62. 1 250 000/305 000= 4.09(2,260,050) = The amount of warrants the preferred share holders are entitled to receive as part of the preferred share units There is also warrants exercisible at $1.25 We should assume that the rest of the warrants went to Marathon This chart pattern, and the way to price closed today, is almost a sure fire indication that they are unloading some of those warrants. Cheers, and happy trading everyone. **********WE ARE NOT FINANCIAL ADVISERS. THIS IS A HIGH RISK TRADE. CONSULT A FINANCIAL ADVISER BEFORE BUYING ANY PUBLICLY TRADED SECURITY. WE DO NOT OWN THIS STOCK, NOR DO WE INTEND TO BUY THIS STOCK IN THE NEAR FUTURE. WE ARE NOT BEING PAID TO WRITE THIS OR BEING COMPENSATED IN ANYWAY. YOU SHOULD NOT USE THIS INFORMATION AS INVESTMENT ADVISE. ALSO, BY READING THIS ARTICLE, YOU AGREE TO INDEMNIFY US OF ALL LIABILITY FOR ANY LOSSES INCURRED FROM USING OUR INFORMATION AS THE BASIS OF AN INVESTMENT DECISION *****
NASDAQ:WKHSShort
by InteractiveSwingTrading
1